Cardiovascular effects of EGFR (epidermal growth factor receptor) monoclonal antibodies

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 8, Issue 3, 2010, Pages 156-163

  Chaudhary, Preeti ^a   Gajra, Ajeet ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Cardiotoxicity; Cetuximab; EGFR; mAbs; Panitumumab

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC METAL COMPLEX; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DIPHENHYDRAMINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MONOCLONAL ANTIBODY; NAVELBINE; OXALIPLATIN; PANITUMUMAB; PLATINUM;

ABDOMINAL PAIN; ACNE; ADD ON THERAPY; AGING; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BRADYCARDIA; BRONCHOSPASM; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DYSPNEA; ECG ABNORMALITY; EXTERNAL BEAM RADIOTHERAPY; HEAD AND NECK CARCINOMA; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERSENSITIVITY REACTION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; HYPOXIA; INCIDENCE; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LUNG EDEMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALAISE; METASTASIS; MYOCARDITIS; NAUSEA; NEOPLASM; NEPHROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; OVARY CANCER; PANCREAS CANCER; PERICARDITIS; PNEUMONIA; POPULATION; QT PROLONGATION; SEPSIS; SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; SUDDEN DEATH; TAKOTSUBO CARDIOMYOPATHY; THROMBOEMBOLISM; URTICARIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOVASCULAR DISEASES; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77954724869     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152510791698370     Document Type: Article

References (71)

1. Wells, A. EGF receptor. Int. J. Biochem. Cell. Biol., 1999, 31(6), 637-643.
2. Gullick, W.J. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull., 1991, 47(1), 87-98.
3. Salomon, D.S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 1995, 19, 183-232.
4. Astsaturov, I.; Cohen R.B.; Harari, P.M. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr. Cancer Drug Targets, 2006, 6, 691-710.
5. Li, S.; Schmitz, K.R.; Jeffery, P.D.; Wiltzius, J.J.; Kussie, P.; Ferguson, K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell, 2005, 7(4), 301-311.
6. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med., 2004, 351, 337-345.
7. Bonner, J.A.; Harari, P.M.; Giralt, J.; Azarnia, N.; Shin, D.M.; Cohen, R.B.; Jones, C.U.; Sur, R.; Raben, D.; Jassem, J.; Ove, R.; Kies, M.S.; Baselga, J.; Youssoufian, H.; Amellal, N.; Rowinsky, E.K.; Ang, K.K. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N. Engl. J. Med., 2006, 354(6), 567-578.
8. Kullmann, F.; Hollerbach, S.; Dollinger, M.M.; Harder, J.; Fuchs, M.; Messmann, H.; Trojan, J.; Gäbele, E.; Hinke, A.; Hollerbach, C.; Endlicher, E. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br. J. Cancer, 2009, 100(7), 1032-1036.
9. Rosell, R.; Robinet, G.; Szczesna, A.; Ramlau, R.; Constenla, M.; Mennecier, B.C.; Pfeifer, W.; O'Byrne, K.J.; Welte, T.; Kolb, R.; Pirker, R.; Chemaissani, A.; Perol, M.; Ranson, M.R.; Ellis, P.A.; Pilz, K.; Reck, M. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann. Oncol., 2008, 19(2), 362-369.
10. Hanna, N.; Lilenbaum, R.; Ansari, R.; Lynch, T.; Govindan, R.; Jänne, P.A.; Bonomi, P. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J. Clin. Oncol., 2006, 24(33), 5253-5258.
11. Konner, J.; Schilder, R.J.; DeRosa, F.A.; Gerst, S.R.; Tew, W.P.; Sabbatini, P.J.; Hensley, M.L.; Spriggs, D.R.; Aghajanian, C.A. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol. Oncol., 2008, 110(2), 140-145.
12. Elez, E.; Macarulla, T.; Tabernero, J. Handling side-effects of targeted therapies: safety of targeted therapies in solid tumors. Ann. Oncol., 2008, 19(Suppl 7), vii146-52.
13. Klapper, L.N.; Kirschbaum, M.H.; Sela, M.; Yarden, Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer. Res., 2000, 77, 25-79.
14. Baselga, J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur. J. Cancer, 2001, 37(Suppl 4), S16-S22.
15. Goldstein, N.I.; Prewett, M.; Zukulys, K.; Rockwell, P.; Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth receptor in a human tumor xenograft model. Clin. Cancer Res., 1995, 1(11), 1311-1318.
16. Amgen., Vectibix (panitumumab) package insert. Thousand Oaks, CA, 2006.
17. Wu, X.; Rubin, M.; Fan, Z.; DeBlasio, T.; Soos, T.; Koff, A.; Mendelsohn, J. Involvement of p27kipl in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Onco gene, 1996, 12, 1397-1403.
18. Peng, D.; Fan, Z.; Lu, Y.; Blasio, T.; Scher, H.; Mendelsohn, J. Antiepidermal growth factor receptor monoclonal antibody 225 upregulates p27kipl and induces G1 arrest in prostatic cancer cell line DU145. Cancer. Res., 1996, 56, 3666-3669.
19. Huang, S.M.; Bock, J.M.; Harari, P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer. Res., 1999, 59, 1935-1940.
20. Zhao, Y.Y.; Sawyer, D.R.; Baliga, R.R.; Opel, D.J.; Han, X.; Marchionni, M.A.; Kelly, R.A. Neuregulins promote survival and growth of cardiac myocytes: persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J. Biol. Chem., 1998, 273, 10261-10269.
21. Carraway, K.L. Involvement of the neuregulins and their receptors in cardiac and neural development. Bioessays. 1996, 18, 263-266.
22. Erickson, S.L.; O'Shea, K.S.; Ghaboosi,; Loverro, L.; Frantz, G.; Bauer, M.; Lu, L.H.; Moore, M.W. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2 and heregulin-deficient mice. Development, 1997, 124, 4999-5011.
23. Zhao, Y.Y.; Feron, O.; Dessy, C.; Han, X.; Marchionni, M.A.; Kelly, R.A. Neuregulin signaling in the heart: dynamic targeting of erbB4 to caveolar microdomains in cardiac myocytes. Circ. Res., 1999, 84, 1380-1387.
24. Petit, A.M.V.; Rak, J.; Hung, M.C.; Rockwell, P.; Goldstein, N.; Fendly, B.; Kerbel, R.S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. Am. J. Pathol., 1997, 151, 1523-1530.
25. Bruns, C.J.; Harbison, M.T.; Davis, D.W.; Portera, C.A.; Tsan, R.; McConkey, D.J.; Evans, D.B.; Abbruzzese, J.L.; Hicklin, D.J.; Radinsky, R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer. Res., 2000, 6, 1936-1948.
26. Perrotte, P.; Matsumoto, T.; Inoue, K.; Kuniyasu, H.; Eve, B.Y.; Hicklin, D.J.; Radinsky, R.; Dinney, C.P. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res., 1999, 5(2), 257-265.
27. Schrag, D.; Chung, K.Y.; Flombaum, C.; Saltz, L. Cetuximab therapy and symptomatic hypomagnesemia. J. Natl. Cancer. Inst., 2005, 97, 1221-1224.
28. Fakih, M. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach? Expert. Rev. Anticancer. Ther., 2008, 8(9), 1471-1480.
29. Fakih, M.G.; Wilding, G.; Lombardo, J. Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin. Colorectal. Cancer, 2006, 6, 152-156.
30. Burtness, B.; Goldwasser, M.A.; Flood, W.; Mattar, B.; Forastiere, A.A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an eastern Cooperative Oncology group study. J. Clin. Oncol., 2005, 23, 8646-8654.
31. Castillo, L.; Etienne-Grimaldi, M.C.; Fischel, J.L.; Formento, P.; Magné, N.; Milano, G. Pharmacological Background of EGFR targeting. Ann. Oncol., 2004, 15, 1007-1012.
32. Package insert. Erbitux (cetuximab). Branchburg, NJ: Imclone, Systems and Bristol-Myers Squibb, June 2004.
33. Gebbia, V.; Del Prete, S.; Borsellino, N.; Ferraù, F.; Tralongo, P.; Verderame, F.; Leonardi, V.; Capasso, E.; Maiello, E.; Bordonaro, R.; Stinco, S.; Agostara, B.; Barone, C. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. Clin. Colorectal. Cancer, 2006, 5(6), 422-428.
34. Needle, M.N. Safety experience with IMC-C225, an epidermal growth factor receptor antibody. Semin. Oncol., 2002, 29(5 Suppl 14), 55-60.
35. Saltz, L.B.; Meropol, N.J.; Loehrer, P.J. Sr.; Needle, M.N.; Kopit, J.; Mayer, R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol., 2004, 22(7), 1201-1208.
36. Cheifetz, A.; Mayer, L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt. Sinai. J. Med., 2005, 72(4), 250-256.
37. Pendley, C.; Schantz, A.; Wagner, C. Immunogenicity of therapeutic monoclonal antibodies. Curr. Opin. Mol. Ther., 2003, 5(2), 172-179.
38. Mendelsohn, J.; Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol., 2003, 21(14), 2787-2799.
39. Hoy, S.M.; Wagstaff, A.J. Panitumumab: in the treatment of metastatic colorectal cancer. Drugs, 2006, 66, 2005-2014: discussion 2015-2016.
40. van Cutsem, E.; Peeters, M.; Siena, S; Humblet, Y.; Hendlisz, A.; Neyns, B.; Canon, J.L.; Van Laethem, J.L.; Maurel, J.; Richardson, G.; Wolf, M.; Amado, R.G. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol., 2007, 25(13), 1658-1664.
41. Mell, L.K.; Weichselbaum, R.R. More on cetuximab in head and neck cancer. N. Engl. J.Med., 2007, 357, 2201-2202.
42. Yeh, E.T. Cardiotoxicity induced by chemotherapy and antibody therapy. Ann. Rev. Med., 2006, 57, 485-498.
43. Prod Info ERBITUX (R) IV injection, 2008.
44. Albanell, J.; Baselga, J. Systemic therapy emergencies Semin. Oncol., 2000, 27(3), 347-361.
45. Mellstedt, H. Monoclonal antibodies in human cancer. Drugs Today (Barc.), 2003, 39(Suppl C), 1-16.
46. Pfister, D.G.; Su, Y.B.; Kraus, D.H.; Wolden, S.L.; Lis, E.; Aliff, T.B.; Zahalsky, A.J.; Lake, S.; Needle, M.N.; Shaha, A.R.; Shah, J.P.; Zelefsky, M.J. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combinedmodality paradigm. J.Clin. Oncol., 2006, 24(7), 1072-1078.
47. Vermorken, J.B.; Mesia Ricard,; Rivera, F.; Remenar, E.; Kawecki, A.; Rottey, S.; Erfan, J.; Zabolotnyy, D.; Kienzer, H.R.; Cupissol, D.; Peyrade, F.; Benasso, M.; Vynnychenko, I.; De Raucourt, D.; Bokemeyer, C.; Schueler, A.; Amellal, N.; Hitt, R. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N. Eng. J. Med., 2008, 359, 1116-1127.
48. Kim, L.; Karas, M.; Chiu Wong, S. Chemotherapy induced Takotsubo cardiomyopathy J. Invasive Cardiol., 2008, 20(12), E338-E340.
49. Berlin, J.; Posey, J.; Tchekmedyian, S.; Hu, E.; Chan, D.; Malik, I.; Yang, L.; Amado, R.G.; Hecht, J.R. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin. Colorectal. Cancer, 2007, 6, 427-432.
50. Amgen discontinues Vectibix treatment in PACCE trial evaluating Vectibix as part of triple combination regimen [press release]. Thousand Oaks, CA: Amgen; March 22, 2007. [Accessed: March 22, 2007]. Available from: http://www.amgen.com/searchresults.jsp?searchSite=amgendotcom&searchRequestHandler=searchresults.jsp&searchString=pacce+trial
51. Tejpar, S.; Piessevaux, H.; Claes, K.; Piront, P.; Hoenderop, J.G.; Verslype, C.; Van Cutsem, E. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol., 2007, 8(5), 366-367.
52. Thomas, S.E.; Anderson, S.; Gordon, K.L.; Oyama, T.T.; Shankland, S.J.; Johnson, R.J. Tubulointerstitial disease in aging: evidence for underlying peritubular capillary damage, a potential role for renal ischemia. J. Am. Soc. Nephrol., 1998, 9, 231-242.
53. Sobrero, A.F.; Maurel, J.; Fehrenbacher, L.; Scheithauer, W.; Abubakr, Y.A.; Lutz, M.P.; Vega-Villegas, M.E.; Eng, C.; Steinhauer, E.U.; Prausova, J.; Lenz, H.J.; Borg, C.; Middleton, G.; Kröning, H.; Luppi, G.; Kisker, O.; Zubel, A.; Langer, C.; Kopit, J.; Burris, H.A. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol., 2008, 26(14), 2311-2319
54. Pirker, R.; Pereira, J.R.; Szczesna, A.; von Pawel, J.; Krzakowski, M.; Ramlau, R.; Vynnychenko, I.; Park, K.; Yu, C.T.; Ganul, V.; Roh, J.K.; Bajetta, E.; O'Byrne, K.; de Marinis, F.; Eberhardt, W.; Goddemeier, T.; Emig, M.; Gatzemeier, U. FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced nonsmall-cell lung cancer(FLEX): an open -label randomized phase III trial. Lancet, 2009, 373(9674), 1525-1531.
55. Changes in Erbitux Package Insert From: Richard Pazdur, M.D. Director, Division of Oncology Drug Products, Center for Drug Evaluation and Research, available at FDA http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyRelatedDrugLabelingChanges/ucm122974.htm
56. Lieberman, P.; Kemp, S.F.; Oppenheimer, J. The diagnosis and management of anaphylaxis: an updated practice primer. Joint Task Force on practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol., 2005, 115, S483-S523.
57. Bourhis, J.; Rivera, F.; Mesia, R.; Awada, A.; Geoffrois, L.; Borel, C.; Humblet, Y.; Lopez-Pousa, A.; Hitt, R.; Vega Villegas, M.E.; Duck, L.; Rosine, D.; Amellal, N.; Schueler, A.; Harstrick, A. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol., 2006, 24, 2866-2872.
58. Baselga, J.; Trigo, J.M.; Bourhis, J.; Tortochaux, J.; Cortes-Funes, H.; Hitt, R.; Gascon, P.; Amellal, N.; Harstrick, A.; Eckardt, A. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol., 2005, 23, 5568-5577.
59. Xiong, H.Q.; Rosenberg, A.; LoBuglio, A.; Schmidt, W.; Wolff, R.A.; Deutsch, J.; Needle, M.; Abbruzzese, J.L. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J. Clin.Oncol., 2004, 22, 2610-2616.
60. Machiels, J.P.; Sempoux, C.; Scalliet, P.; Coche, J.C.; Humblet, Y.; Van, C.E.; Kerger, J.; Canon, J.L.; Peeters, M.; Aydin, S.; Laurent, S.; Kartheuser, A.; Coster, B.; Roels, S.; Daisne, J.F.; Honhon, B.; Duck, L.; Kirkove, C.; Bonny, M.A.; Haustermans, K. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann. Oncol., 2007, 18, 738-744.
61. Safran, H.; Suntharalingam, M.; Dipetrillo, T.; Ng, T.; Doyle, L.A.; Krasna, M.; Plette, A.; Evans, D.; Wanebo, H.; Akerman, P.; Spector, J.; Kennedy, N.; Kennedy, T. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int. J. Radiat. Oncol. Biol. Phys., 2008, 70, 391-395.
62. Ibrahim, E.; Zeeneldin, A.; Al-Gahmi, A.; Sallam, Y.; Fawzi, E.; Bahadur, Y. Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer. Indian J. Cancer, 2007, 44, 56-61.
63. Vincenzi, B.; Santini, D.; Rabitti, C.; Coppola, R.; Beomonte, Z.B.; Trodella, L.; Tonini, G. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br. J. Cancer, 2006, 94, 792-797.
64. Tol, J.; Koopman, M.; Cats, A.; Creemers, G.J.; Schrama, J.G.; Erdkamp, F.L.; Vos, A.H.; Mol, L.; Antonini, N.F.; Punt, C.J. A randomized phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann. Oncol., 2008, 19, 734-738.
65. Secord, A.A.; Blessing, J.A.; Armstrong, D.K.; Rodgers, W.H.; Miner, Z.; Barnes, M.N.; Lewandowski, G.; Mannel, R.S. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol. Oncol., 2008, 108, 493-499.
66. Butts, C.A.; Bodkin, D.; Middleman, E.L.; Englund, C.W.; Ellison, D.; Alam, Y.; Kreisman, H.; Graze, P.; Maher, J.; Ross, H.J.; Ellis, P.M.; McNulty, W.; Kaplan, E.; Pautret, V.; Weber, M.R.; Shepherd, F.A. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J. Clin. Oncol., 2007, 25, 5777-5784.
67. Rodel, C.; Arnold, D.; Hipp, M.; Liersch, T.; Dellas, K.; Iesalnieks, I.; Hermann, R.M.; Lordick, F.; Hinke, A.; Hohenberger, W.; Sauer, R. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int. J. Radiat. Oncol. Biol. Phys., 2008, 70, 1081-1086.
68. Belani, C.P.; Schreeder, M.T.; Steis, R.G.; Guidice, R.A.; Marsland, T.A.; Butler, E.H.; Ramalingam, S.S. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advancedstage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer, 2008, 113, 2512-2517.
69. Gridelli, C.; Morabito, A.; Gebbia, V.; Mencoboni, M.; Carrozza, F.; Vigano, M.G.; Verusio, C.; Bollina, R.; Mattioli, R.; Valerio, M.R.; Valmadre, G.; Maione, P.; Rossi, A.; Cascone, T.; Morgillo, F.; Di, M.M.; Piccirillo, M.C.; Gallo, C.; Perrone, F.; Ciardiello, F. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer, 2010, 67(1), 86-92.
70. Shin, D.M.; Donato, N.J.; Perez-Soler, R.; Shin, H.J.; Wu, J.Y.; Zhang, P.; Lawhorn, K.; Khuri, F.R.; Glisson, B.S.; Myers, J.; Clayman, G.; Pfister, D.; Falcey, J.; Waksal, H.; Mendelsohn, J.; Hong, W.K. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res., 2001, 7, 1204-1213.
71. Giusti, R.M.; Cohen, M.H. FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer. Oncologist, 2009, 14(3), 284-290.